Finance

Lists
Why is NGNE up 3.41%?
Dive Deeper
NGNE:NASDAQ
Neurogene Inc
$27.58
+3.41%
(+0.91) 1D
$27.58
0.00% (0.00)
After hours
Closed: Nov 4, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NGNE...
Open
$27.79
High
$28.10
Low
$26.15
Mkt. cap
551.91M
Avg. vol.
314.31K
Volume
208.91K
52-wk high
$43.66
52-wk low
$15.93
EPS
-$5.03
Beta
1.75
Shares outstanding
20.01M
No. of employees
131
Open
$27.79
High
$28.10
Low
$26.15
Mkt. cap
551.91M
Avg. vol.
314.31K
Volume
208.91K
52-wk high
$43.66
52-wk low
$15.93
EPS
-$5.03
Beta
1.75
Shares outstanding
20.01M
No. of employees
131
News stories
From web sources and news partners
About Neurogene Inc
CEOJonathan Drachman M.D.
Employees131
Founded2018
Headquarters-
SectorBiotechnology
Industry-
Websiteneurogene.com
Analyst ratings
Based on 8 analysts giving stock ratings to NGNE in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for NGNE in the last 3 months.
Highest
Current $27.58
$166.00 (+501.89%)
Average
$80.17 (+190.68%)
Lowest
$46.00 (+66.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$166.00
+501.9%
10/28/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$65.00
+135.7%
10/28/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$46.00
+66.8%
10/08/2026
Priyanka Grover
J.P. Morgan
Buy
Initiated
$60.00
+117.5%
10/08/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$81.00
+193.7%
08/11/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
08/11/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/11/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$63.00
+128.4%
08/11/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$70.00
+153.8%
06/03/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$65.00
+135.7%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
17.24M
20.52M
25.15M
25.47M
Cost of revenue
17.24M
20.52M
25.15M
25.47M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.56M
6.89M
8.20M
11.20M
Operating expense
6.56M
6.89M
8.20M
11.20M
Total operating expenses
23.80M
27.41M
33.35M
36.67M
Operating income
-23.80M
-27.41M
-33.35M
-36.67M
Other non operating income
107.00K
122.00K
154.00K
136.00K
EBT including unusual items
-20.95M
-24.74M
-30.93M
-34.49M
EBT excluding unusual items
-20.95M
-24.62M
-30.93M
-34.49M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.95M
-24.74M
-30.93M
-34.49M
Net profit margin
-
-
-
-
Earnings per share
-0.99
-1.13
-1.39
-1.53
Interest and investment income
2.74M
2.67M
2.26M
2.05M
Interest expense
-1.00K
-1.00K
-
-
Net interest expenses
2.74M
2.67M
2.26M
2.05M
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.02M
-26.62M
-32.50M
-35.85M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps